Bristol Myers Squibb (BMY) Acquisitions (2009 - 2026)

Bristol Myers Squibb has disclosed Acquisitions across 16 years of filings, most recently posting $65.0 million for Q1 2026.

• In Q1 2026, Acquisitions fell 16.67% year-over-year to $65.0 million; the TTM figure through Mar 2026 stood at $3.9 billion (up 112.95% YoY), while the FY2025 annual figure was $3.9 billion, down 81.93% from the prior year.
• Acquisitions eased to $65.0 million in Q1 2026, from $1.7 billion in the prior quarter.
• Over the last five years, Acquisitions for BMY reached as high as $20.1 billion in Q1 2024 and fell as low as $47.0 million in Q4 2024.
• The 5-year median for Acquisitions is $348.0 million (2024), against an average of $1.8 billion.
• Annual changes were most pronounced in 2024 — Acquisitions jumped 25608.97% — and 2025, when it plunged 99.61%.
• A 5-year view of Acquisitions shows it stood at $116.0 million in 2022, then jumped by 400.86% to $581.0 million in 2023, then slumped by 91.91% to $47.0 million in 2024, then jumped by 3531.91% to $1.7 billion in 2025, then plunged by 96.19% to $65.0 million in 2026.
• According to Business Quant data, Acquisitions over the past three periods registered $65.0 million, $1.7 billion, and $1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.